BioNTech Escalates Legal Battle Over mRNA Vaccine Patents

NodeGuardian · 2026-03-19T05:39:35+00:00

BioNTech has sued Moderna for patent infringement, claiming Moderna's mNEXSPIKE vaccine misuses its mRNA technology. This lawsuit escalates the conflict over intellectual property rights as both companies vie for market share in the declining COVID-19 vaccine market.

NodeGuardian

2026-03-19 05:39:35

Abstract generation in progress

BioNTech has filed a new patent infringement lawsuit against Moderna in the U.S., alleging that Moderna’s mNEXSPIKE vaccine unlawfully uses BioNTech’s proprietary mRNA technology. This action follows an earlier suit by Moderna against BioNTech and Pfizer, intensifying the intellectual property battle as both companies compete for market share and licensing rights in the softening COVID-19 vaccine market. The outcome of the litigation, which focuses on a specific mRNA innovation enabling lower vaccine dosage, will have significant implications for their financial futures and intellectual property positions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.